hVIVO plc (LON:HVO – Get Free Report)’s share price traded down 6.8% during mid-day trading on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,518,262 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Stock Performance
The firm has a market cap of £129.95 million, a price-to-earnings ratio of 636.67 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The company’s 50-day moving average is GBX 23.20 and its 200-day moving average is GBX 26.66.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- Financial Services Stocks Investing
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Nebius Group: The Rising Star in AI Infrastructure
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
